Polyendocrine metabolic ovarian syndrome (PMOS) is the new name for polycystic ovary syndrome (PCOS). The updated term better reflects what patients and clinicians have long recognized: this is not simply an ovarian-cyst condition. It is a variable, lifelong pattern involving androgen hormones, ovulation, reproductive health, glucose regulation, cardiovascular risk, and sometimes psychological and sleep health.
The name changed in May 2026, when an international consensus introduced "polyendocrine metabolic ovarian syndrome" and the American Society for Reproductive Medicine endorsed PMOS. During the transition, health records, test pages, research papers, and patient searches may still use PCOS. The two terms refer to the same syndrome.
Laboratory testing can help identify biochemical androgen excess, exclude other explanations for irregular periods or excess hair growth, and measure metabolic risks that may not cause symptoms. It cannot diagnose PMOS from one result. A qualified healthcare professional must integrate laboratory findings with menstrual history, physical signs, medications, fertility goals, and, when needed, ultrasound or anti-Mullerian hormone (AMH).
Ulta Lab Tests provides access to many relevant blood tests online where available, helping patients establish objective baselines and prepare for more informed conversations with a gynecologist, endocrinologist, primary-care clinician, or reproductive endocrinologist. Testing is informational and does not replace professional medical evaluation.
Polyendocrine metabolic ovarian syndrome is a common endocrine condition characterized by varying combinations of excess androgen activity, irregular or absent ovulation, and polycystic ovarian morphology. The World Health Organization estimates that the condition affects about 10% to 13% of reproductive-aged women worldwide and that many affected women remain undiagnosed.
The word "polycystic" in the former name caused understandable confusion. The follicles seen on an ultrasound are not the same as typical ovarian cysts, and a person does not need ovarian cysts - or even polycystic ovarian morphology - to meet diagnostic criteria. Conversely, an ultrasound that shows polycystic-appearing ovaries does not prove that the syndrome is present.
PMOS can look different from one person to another. One person may seek care for unpredictable periods and acne. Another may have apparently regular bleeding but inconsistent ovulation. Another may first learn about the pattern during infertility care or after abnormal glucose and triglyceride results. Symptoms can also change with age, weight, pregnancy, hormonal contraception, medications, and the transition toward menopause.
After other plausible causes are excluded, the 2023 International Evidence-based Guideline generally requires at least two of these three features:
If irregular cycles and hyperandrogenism are both present, AMH or ovarian ultrasound is not required for diagnosis. In adolescents, the standard is different: both ovulatory dysfunction and hyperandrogenism are required, while ultrasound and AMH are not recommended for diagnosis because normal pubertal development can resemble PMOS.
PMOS is often recognized because of menstrual changes, unwanted facial or body hair, acne, scalp hair thinning, or difficulty conceiving. Those concerns deserve attention, but the condition can also affect long-term health.
People with PMOS have a higher likelihood of impaired glucose regulation and type 2 diabetes regardless of body mass index. Dyslipidemia, high blood pressure, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease may occur more often. Long intervals without menstruation can expose the endometrium to prolonged unopposed estrogen, increasing the risk of endometrial hyperplasia and cancer, although the absolute chance of endometrial cancer remains low and routine screening is not recommended solely because PMOS is present.
PMOS can also affect quality of life, body image, mood, and eating behavior. These concerns are not explained by a testosterone or glucose result and should not be minimized. A useful evaluation therefore looks beyond a hormone panel and considers the patient's symptoms, priorities, metabolic health, sleep, mental well-being, and reproductive plans.
| Symptom or finding | What it may suggest | Laboratory information that may help |
|---|---|---|
| Cycles shorter than 21 days, longer than 35 days, fewer than eight cycles per year, or a cycle longer than 90 days | Ovulatory dysfunction, pregnancy, thyroid or prolactin disorder, hypothalamic dysfunction, ovarian insufficiency, medication effect, or PMOS | Pregnancy test, TSH with Free T4 when indicated, prolactin, total and free testosterone, SHBG, 17-hydroxyprogesterone; selected FSH, LH, estradiol, or progesterone based on the question |
| New or persistent facial or body hair, acne, or scalp hair thinning | Clinical androgen excess; PMOS is common, but adrenal, medication-related, and rare tumor causes must be considered | Total and free testosterone, SHBG; DHEA-S or androstenedione when needed; 17-hydroxyprogesterone |
| Difficulty conceiving | Inconsistent ovulation, age-related reproductive factors, thyroid or prolactin disorder, tubal or uterine factors, or male-factor infertility | Appropriately timed progesterone, pregnancy testing, TSH, prolactin, and selected reproductive hormones; blood tests do not replace a complete fertility evaluation |
| Increased waist size, acanthosis nigricans, family history of diabetes, or prior gestational diabetes | Increased likelihood of impaired glucose tolerance or diabetes | 75-g oral glucose tolerance test, fasting glucose, A1C, lipid panel, CMP |
| Fatigue, reduced exercise tolerance, or hair shedding | Glucose dysregulation, thyroid disease, anemia, iron deficiency, sleep apnea, medication effects, or another condition; not specific to PMOS | CBC, ferritin and iron studies, TSH, glucose testing, and vitamin B12 when clinically relevant |
| Snoring, unrefreshing sleep, or daytime sleepiness | Possible obstructive sleep apnea, which is more common in PMOS independent of BMI | No blood test diagnoses sleep apnea; glucose, lipids, CBC, and liver markers provide associated risk context, while formal diagnosis requires sleep evaluation |
| Heavy or prolonged uterine bleeding | Anovulatory bleeding, pregnancy-related complication, structural uterine disease, or anemia | Pregnancy test, CBC, ferritin; prompt clinician evaluation may be needed |
| Rapidly progressive hair growth, voice deepening, clitoral enlargement, or rapid muscle change | Virilization that is not typical of routine PMOS and may reflect an androgen-secreting disorder or exposure | Prompt total testosterone and DHEA-S testing within an urgent clinician-directed evaluation |
Seek urgent medical care for severe pelvic or abdominal pain, fainting, very heavy bleeding, a positive pregnancy test with pain or bleeding, severe hyperglycemia symptoms, or other sudden and concerning changes. Rapid virilization, severe headache with visual changes, or new milk production unrelated to pregnancy or breastfeeding also warrants prompt evaluation.
Lab testing can answer four distinct questions:
Lab testing cannot determine the complete diagnosis without context. Clinical hirsutism may establish androgen excess even when testosterone is within the laboratory range. A high AMH may reflect a greater follicle pool but cannot diagnose PMOS alone. A low mid-luteal progesterone may reflect anovulation, but it may also mean the sample was collected at the wrong time. Normal fasting glucose or A1C does not always exclude impaired glucose tolerance.
Trends can be helpful when they track a defined outcome, such as glycemic status, triglycerides, liver enzymes, kidney function, a previous nutrient deficiency, or medication safety. Repeating broad androgen panels after PMOS is established has a limited routine role unless symptoms change unexpectedly or the original result does not fit the clinical pattern.
| Test | What it measures and why it may matter | General pattern meaning and important limitations | Ulta Lab Tests example |
|---|---|---|---|
| Total and free testosterone with SHBG | Assesses circulating testosterone and the fraction available to tissues. These are the preferred biochemical androgen measures. | Elevated results can support biochemical hyperandrogenism. A normal result does not exclude clinical hirsutism or PMOS. LC-MS/MS is preferred for total testosterone; direct immunoassays may be less accurate at concentrations typical in women. | Testosterone Free (Dialysis) and Total MS; Testosterone Total and Free and Sex Hormone Binding Globulin Test |
| DHEA-S | Measures a predominantly adrenal androgen. | Elevation can suggest an adrenal contribution but is not specific to PMOS and generally declines with age. Marked elevation or rapid virilization requires broader evaluation. | DHEA-S Test |
| Androstenedione | Measures an androgen produced by the ovaries and adrenal glands. | It may add information when testosterone is not elevated, but it is less specific and should not be used as a stand-alone PMOS marker. | Androstenedione Test |
| Pregnancy test, hCG | Detects human chorionic gonadotropin. | Pregnancy must be considered first when a period is late or absent. A positive result with pain or bleeding requires prompt medical evaluation. Very early testing can be negative and may need clinician-directed repetition. | Pregnancy Blood Test; hCG Total Qualitative Test |
| TSH with Free T4 when indicated | Evaluates the pituitary-thyroid signal and circulating free thyroxine. | Thyroid dysfunction can disrupt cycles and mimic part of the PMOS pattern. Abnormal TSH should be interpreted with Free T4, symptoms, medications, pregnancy status, and clinical context. | TSH and Free T4 Test; TSH Test with Reflex to Free T4 |
| Prolactin | Measures a pituitary hormone that affects ovulation and lactation. | Persistent elevation can contribute to irregular or absent periods. Mild elevations may reflect stress, sleep, exercise, eating, breast stimulation, medication, or macroprolactin and often require confirmation. | Prolactin Test |
| 17-hydroxyprogesterone | Screens for 21-hydroxylase deficiency, the most common cause of nonclassic congenital adrenal hyperplasia. | An elevated screening result does not establish the diagnosis and may require repeat or stimulation testing. Morning collection and follicular-phase timing are preferred when feasible. | 17-Hydroxyprogesterone Test |
| Progesterone | Measures the hormone that rises after ovulation. | An appropriately timed result can help document ovulation even when bleeding appears regular. A low value may mean no ovulation or simply mistimed collection; a universal "day 21" rule does not fit every cycle. | Progesterone Test |
| FSH, LH, and estradiol | Provide pituitary-ovarian context in selected amenorrhea, ovarian insufficiency, hypothalamic, or fertility evaluations. | These tests are not required for every PMOS evaluation. The LH-to-FSH ratio varies with timing, age, and medication and is not a validated stand-alone diagnostic test. | FSH Test; LH Test; Estradiol Test or an appropriately configured reproductive-hormone panel |
| AMH | Reflects secretion from small ovarian follicles and can help define polycystic ovarian morphology in adults within the diagnostic algorithm. | AMH must not be used alone, is unnecessary when irregular cycles and hyperandrogenism are already present, should not be ordered with ultrasound solely to increase certainty, and is not recommended for adolescent diagnosis. Age, BMI, hormonal contraception, cycle timing, and assay-specific cutoffs affect interpretation. | AMH Test Female |
| Test | What it measures and why it may matter | General pattern meaning and important limitations | Ulta Lab Tests example |
|---|---|---|---|
| 75-g oral glucose tolerance test (OGTT) | Measures fasting and post-glucose-load blood sugar and is the most accurate recommended glycemic assessment in PMOS. | Can identify impaired glucose tolerance that fasting glucose or A1C may miss. It requires preparation, fasting, a timed glucose drink, and completion of the specified collection schedule. | Glucose Tolerance Test 2 Specimens 75g |
| Fasting glucose and A1C | Fasting glucose is a point-in-time measure; A1C estimates average glycemia over roughly two to three months. | Useful when OGTT is not feasible, but less accurate for PMOS-related glycemic assessment. A1C can be affected by anemia, altered red-cell turnover, kidney disease, pregnancy, and hemoglobin variants. | A1c Test; Hemoglobin A1c and Glucose Panel |
| Lipid panel | Measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. | A lipid profile is recommended at diagnosis regardless of age or BMI. High triglycerides, low HDL cholesterol, or elevated LDL cholesterol may show cardiometabolic risk but do not diagnose PMOS. | Lipid Panel Test; Lipid Panel and Comprehensive Metabolic Panel-CMP |
| Comprehensive metabolic panel (CMP) | Includes glucose, electrolytes, kidney markers, liver enzymes, bilirubin, albumin, and proteins. | Helps establish metabolic and medication-safety context. Elevated liver enzymes may warrant evaluation, while normal enzymes do not exclude steatotic liver disease. | Comprehensive Metabolic Panel Test - CMP |
| ApoB, when appropriate | Estimates the number of circulating atherogenic lipoprotein particles. | May add cardiovascular-risk information when triglycerides are high, diabetes or metabolic syndrome is present, or LDL cholesterol and particle burden may be discordant. It is not a routine PMOS diagnostic test. | Apolipoprotein B Test |
| CBC, ferritin, iron studies, and vitamin B12 when indicated | Evaluates anemia, iron status, and selected nutrient concerns that can contribute to fatigue or hair loss. | Abnormalities can explain symptoms that may otherwise be attributed to PMOS. They do not establish PMOS. B12 monitoring may be relevant with long-term metformin use or other deficiency risks. | Complete Blood Count with Differential and Platelets - CBC Test; Ferritin Test; Iron and Total Iron Binding Capacity Test; Vitamin B12 Test |
Insulin resistance is important in PMOS, but the international guideline notes that clinically available insulin assays have limited value in routine care. Fasting insulin should not replace the OGTT, fasting glucose, or A1C for assessing impaired glucose regulation or diabetes.
Before ordering broad testing, document cycle lengths, the number of periods in the past year, any cycle longer than 90 days, hair or acne changes, scalp hair loss, weight and waist trends, pregnancy possibility, fertility goals, current or recent hormonal contraception, medications, supplements, and family history of PMOS or type 2 diabetes.
When appropriate, an initial evaluation may include pregnancy testing, total and free testosterone with SHBG, TSH, prolactin, and 17-hydroxyprogesterone. Free T4 is added when thyroid results or symptoms warrant it. This cluster is intended to answer specific diagnostic questions, not to label every abnormal result as PMOS.
DHEA-S or androstenedione may help when testosterone does not explain clinical hyperandrogenism. Progesterone may help confirm ovulation. FSH, LH, and estradiol may be useful when the differential includes ovarian insufficiency or hypothalamic-pituitary dysfunction. In adults with only one established diagnostic feature, either AMH or ultrasound may help define ovarian morphology; ordering both for the same purpose can increase overdiagnosis.
Cortisol testing is not routine PMOS screening. It belongs in a clinician-directed evaluation when features such as purple abdominal striae, easy bruising, proximal muscle weakness, or other findings raise concern for Cushing syndrome.
The international guideline recommends glycemic assessment for every adult and adolescent with PMOS. The 75-g OGTT is preferred regardless of BMI. If it cannot be performed, fasting glucose and/or A1C may be used with the understanding that sensitivity is lower. A lipid profile is recommended at diagnosis, and blood pressure should be measured at least annually.
Glycemic status is generally reassessed every one to three years, with earlier testing when weight, symptoms, pregnancy plans, medications, or diabetes risk changes. Lipid follow-up depends on the original findings and overall cardiovascular risk. Liver, kidney, potassium, CBC, ferritin, B12, or pregnancy-safety testing should be tailored to medications, previous abnormalities, symptoms, and clinician guidance.
Reference ranges show the interval used by the performing laboratory; they are not a complete diagnostic algorithm. Results can vary with age, biological sex, pregnancy, cycle phase, time of day, fasting status, hydration, recent illness, exercise, medications, supplements, body composition, and assay method. PMOS guidance does not define one universal "optimal" testosterone, insulin, or AMH range that applies to every patient; method-specific reference information and the clinical pattern remain essential.
Hormonal contraception is especially important. Combined oral contraceptives increase SHBG and suppress gonadotropin-dependent androgen production, making testosterone and free-androgen results difficult to interpret. If biochemical androgen testing is essential, the guideline notes that a clinician may consider withdrawal of combined oral contraception for at least three months with reliable alternative contraception. Do not stop contraception or any prescribed medication independently.
Ask these questions when reviewing a result:
An abnormal result does not automatically mean PMOS, and normal results do not always rule it out. The pattern matters more than any isolated number.
Where direct-access testing is available, patients can use Ulta Lab Tests to select many hormone, reproductive, thyroid, glucose, lipid, liver, kidney, and nutrient tests online. Testing is performed through established laboratory networks such as Quest Diagnostics where applicable. Patients can review transparent pricing before ordering, no insurance is required for direct-access purchases, eligible HSA or FSA payment methods may be available where accepted, and results are delivered through a secure online account.
Direct access can make it easier to establish a baseline, follow a clinician-directed monitoring plan, or bring objective information to an appointment. It should not be used to delay care for severe symptoms, pregnancy concerns, prolonged amenorrhea, rapid virilization, or markedly abnormal results.
Yes. Polyendocrine metabolic ovarian syndrome, abbreviated PMOS, is the new name introduced in 2026 for polycystic ovary syndrome, or PCOS. The change does not create a different disease or automatically change a person's diagnosis. It emphasizes that the syndrome involves endocrine, metabolic, ovarian, reproductive, and lifelong health rather than requiring ovarian cysts.
A focused evaluation often includes total and free testosterone with SHBG, pregnancy testing when relevant, TSH, prolactin, and 17-hydroxyprogesterone. DHEA-S, androstenedione, progesterone, FSH, LH, estradiol, or AMH may be added for specific questions. Metabolic assessment commonly includes a 75-g OGTT, fasting glucose, A1C, a lipid panel, and a CMP.
No. PMOS is diagnosed from a connected clinical pattern after alternative causes are excluded. In adults, the pattern generally requires two of three features: hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Blood tests can document biochemical androgen excess, identify look-alike conditions, confirm ovulation, and assess metabolic risk, but they cannot replace menstrual history, examination, and appropriate clinical evaluation.
No. Clinical hirsutism can provide evidence of androgen excess even when a testosterone result falls within the laboratory range. Results can also be affected by assay quality, SHBG, hormonal contraception, and timing. When testosterone is not elevated but the clinical pattern remains convincing, a clinician may consider DHEA-S or androstenedione and review whether the test method was appropriate.
No. In adults, AMH may be used within the diagnostic algorithm as an alternative way to define polycystic ovarian morphology. It should not be used alone, is unnecessary when irregular cycles and hyperandrogenism are already established, and should not be added to ultrasound solely to create more certainty. AMH is not recommended for diagnosing PMOS in adolescents.
The LH-to-FSH ratio is not a validated stand-alone diagnostic test. LH and FSH can be useful in selected amenorrhea, fertility, ovarian insufficiency, or hypothalamic-pituitary evaluations, but their values vary with cycle timing, age, medications, and individual physiology. A normal ratio does not exclude PMOS, and an elevated ratio does not establish it.
Not usually. Insulin resistance is important in PMOS, but current international guidance states that routinely available insulin assays have limited clinical relevance. Fasting insulin and HOMA-IR should not replace validated glycemic testing. The 75-g OGTT is the most accurate assessment; fasting glucose and A1C are alternatives when an OGTT cannot be completed.
Progesterone should be timed to the expected mid-luteal phase, commonly about seven days before the next anticipated period. Calendar day 21 only fits a roughly 28-day cycle. A low result can reflect absent ovulation or incorrect timing, so it should be interpreted with cycle length, bleeding records, fertility treatment, and the laboratory's reference information.
Combined hormonal contraception raises SHBG and suppresses gonadotropin-dependent androgen production, making testosterone and free-androgen assessment difficult. It can also affect AMH and ovarian morphology. If testing while off contraception is medically necessary, the timing and reliable alternative contraception must be planned with the prescribing clinician. Patients should not stop birth control on their own for laboratory testing.
International guidance recommends reassessing glycemic status about every one to three years, depending on individual diabetes risk, prior results, weight changes, pregnancy plans, symptoms, and medications. Lipid follow-up is based on the initial profile and overall cardiovascular risk. A healthcare professional can create a schedule that avoids both missed risk and unnecessary repeat testing.
Many relevant tests can be ordered directly online through Ulta Lab Tests where permitted. Direct access can help establish a baseline or support clinician-directed follow-up, but it does not make every test appropriate for every person and does not independently diagnose PMOS. Review abnormal or confusing results with a qualified healthcare professional, especially when pregnancy, prolonged amenorrhea, infertility, rapid symptom progression, or severe metabolic abnormalities are involved.
Polyendocrine metabolic ovarian syndrome is best understood as a hormonal, ovulatory, reproductive, and metabolic pattern - not an ovarian-cyst diagnosis and not a single abnormal laboratory value. A careful evaluation connects cycle history with accurate androgen testing, excludes pregnancy and endocrine look-alikes, uses AMH or ultrasound only when ovarian morphology is genuinely needed, and measures glucose and lipid risk even when a person feels well.
Ulta Lab Tests can help patients access relevant hormone and metabolic testing, establish useful baselines, and track selected markers over time. Explore the appropriate women's hormone tests, reproductive hormone tests, and glucose screening tests, then review the results with a qualified healthcare provider who can integrate the complete clinical pattern.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
